Objective: To evaluate the efficacy and safety of DM/Q (capsules containing dextromethorphan [DM] and quinidine [Q]) compared with placebo, taken twice daily, for the treatment of pseudobulbar affect over a 12-week period in multiple sclerosis patients.
Methods: A total of 150 patients were randomized in a double-blind, placebo-controlled study to assess pseudobulbar affect with the validated Center for Neurologic Study-Lability Scale. Each patient also recorded the number of episodes experienced between visits, estimated quality of life and quality of relationships on visual analog scales, and completed a pain rating scale.
Results: Patients receiving DM/Q had greater reductions in Center for Neurologic Study-Lability Scale scores than those receiving placebo (p < 0.0001) at all clinic visits (days 15, 29, 57, and 85). All secondary end points also favored DM/Q, including the number of crying or laughing episodes (p
Interpretation: Results in multiple sclerosis patients were similar to those of a previous study in amyotrophic lateral sclerosis, demonstrating that DM/Q may be beneficial in treating potentially disabling pseudobulbar affect in a variety of neurological disorders.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ana.20828 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pseudobulbar Affect Correlates with Mood Symptoms and Low Quality of Life in Patients with Parkinson's Disease: A Comprehensive Cross-Sectional Study.
Sisli Etfal Hastan Tip Bul
December 2024
Department of Neurology, Sancaktepe Sehit Prof. Dr. Ilhan Varank Training and Research Hospital, Istanbul, Türkiye.
Objectives: Despite being recognized for a long time as a characteristic of Parkinson's disease (PD), pseudobulbar affect (PBA) is still a symptom that is underdiagnosed and undertreated. This study aimed to assess the association between PBA and various mood disturbances, as well as the impact on quality of life in PD patients.
Methods: Sixty-eight patients with PD were enrolled in this study.
Cerebral adrenoleukodystrophy presenting as status epilepticus: Unveiling the neurological maze.
Radiol Case Rep
January 2025
Department of General Medicine, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research, Wardha, India.
Article Synopsis
- A 7-year-old boy presented with severe seizures and neurological decline, initially showing symptoms like visual changes and cognitive deterioration over six months.
- MRI scans indicated white matter lesions and elevated serum levels of certain fatty acids, leading to a provisional diagnosis of X-linked cerebral adrenoleukodystrophy (ALD).
- Despite treatment, the patient's condition worsened to blindness and a vegetative state, underscoring the need for early diagnosis and intervention to manage ALD more effectively.
Suspected Pseudobulbar Affect in Neurodegenerative Disease.
Int J Geriatr Psychiatry
October 2024
Department of Neurology, Boston University School of Medicine, Boston, Massachusetts, USA.
Objective: To investigate the association between suspected pseudobulbar affect (PBA), clinical diagnosis, cognitive testing, and self-reported mood in older adults presenting for evaluation of dementia.
Participants: Patients presenting to an outpatient memory disorders clinic (N = 311).
Methods: We used traditional and novel network modeling approaches to examine associations between neuropsychological (NP) tests, patient and clinician rating scales, and the Center for Neurological Study-Lability Scale (CNS-LS) among patients with suspected AD (n = 133) and other neurocognitive diagnosis (n = 178).
Subcortical grey matter involvement in ALS and PLS - vulnerable hubs of cortico-cortical and cortico-basal circuits: extrapyramidal, cognitive, bulbar and respiratory correlates.
Amyotroph Lateral Scler Frontotemporal Degener
February 2025
Computational Neuroimaging Group, School of Medicine, Trinity College Dublin, Dublin, Ireland and.
Article Synopsis
- Neuroimaging studies indicate that the main symptoms of ALS are linked to issues within specific neural networks, particularly those involving deep cerebral and cerebellar nuclei.
- Recent research has found significant changes in brain structures such as volume reductions and metabolic alterations, especially in areas like the thalamus and hippocampus, even before symptoms appear.
- Understanding ALS may require a focus on the integrity of these neural networks, as dysfunction in subcortical nuclei correlates with various clinical symptoms, emphasizing the need for thorough assessments of these brain regions.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!